Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Original Research

False-negative real-time polymerase chain reaction tests in COVID-19 patients: an epidemiological analysis of 302 patients

V. Caramello\textsuperscript{a,*,f}, A. Macciotta\textsuperscript{b,f}, A.V. De Salve\textsuperscript{a}, A. Mussa\textsuperscript{a}, A.M. De Leo\textsuperscript{a}, F. Bar\textsuperscript{a}, D. Panno\textsuperscript{i}, F. Nota\textsuperscript{a}, C.Y.G. Ling\textsuperscript{a}, F. Solitro\textsuperscript{c}, F. Ricceri\textsuperscript{b,d}, C. Sacerdote\textsuperscript{e}, A. Bocuzzi\textsuperscript{a}

\textsuperscript{a} Emergency Department and High Dependency Unit, San Luigi Gonzaga University Hospital, Regione Gonzola 10, Turin, Orbassano, Italy
\textsuperscript{b} Department of Clinical and Biological Science, University of Turin, Regione Gonzola 10, Turin, Italy
\textsuperscript{c} Radiology Department, San Luigi Gonzaga University Hospital, Regione Gonzola 10, Turin, Orbassano, Italy
\textsuperscript{d} Epidemiology Unit, Regional Health Service ASL TO3, Turin, Grugliasco, Italy
\textsuperscript{e} Unit of Cancer Epidemiology, Citt\'a della Salute e della Scienza University Hospital, Turin, Italy

Abstract

Objectives: Patients who arrive at the emergency department (ED) with COVID-19, who test negative at the first real-time polymerase chain reaction (RT-PCR), represent a clinical challenge. This study aimed to evaluate if the clinical manifestation at presentation, the laboratory and imaging results, and the prognosis of COVID-19 differ in patients who tested negative at the first RT-PCR compared with those who tested positive and also to evaluate if comorbid conditions patient-related or the period of arrival are associated with negative testing.

Study design: We retrospectively collected clinical data of patients who accessed the ED from March 1 to May 15, 2020.

Methods: We compared clinical variables, comorbid conditions, and clinical outcomes in the two groups by univariate analysis and logistic regression.

Results: Patients who tested negative at the first RT-PCR showed a higher prevalence of cardiopathy, immunosuppression, and diabetes, as well as a higher leukocyte and lower lymphocyte counts compared with patients who tested positive. A bilateral interstitial syndrome and a typical pattern at computed tomography scan were prevalent in the test-negative group. Test-negative patients were more likely to be admitted to the hospital but less likely to need admission in a high level of care ward. The false-negative rate increased from March to May.

Conclusion: False-negative RT-PCR COVID-19 patients present a similar spectrum of symptoms compared with positive cohort, but more comorbidities. Imaging helps to identify them. True positives had a higher risk of serious complications.

© 2021 The Royal Society for Public Health. Published by Elsevier Ltd. All rights reserved.

Introduction

After the COVID-19 outbreak, the broad clinical spectrum of symptoms and severity of this new syndrome has been widely described\textsuperscript{1} in patients confirmed to have the disease by SARS-CoV-2 RNA detection by real-time polymerase chain reaction (RT-PCR) in upper airways swab.\textsuperscript{2–4} At the very beginning of the pandemic, Xie et al. described the case of five “false-negative” patients\textsuperscript{5} detected by chest computed tomography (CT). Thereafter, many other similar reports occurred,\textsuperscript{5–9} mostly diagnosed by typical findings at chest CT.\textsuperscript{6–9} The “threat” of false-negative worried many authors,\textsuperscript{6–11} but the best diagnostic strategy is still controversial,\textsuperscript{11–13} and the management of these cases raises some pragmatic questions about isolation, infection control, and prognosis.\textsuperscript{10,11} The rate of patients presenting with COVID-19-like syndromes with a negative RT-PCR swab was estimated from 2% to 30%,\textsuperscript{10–17} but this measure could be underestimated because of the lack of an alternative gold standard and because these subjects are often excluded from trials.\textsuperscript{1} Technical preanalytical and analytical issues,\textsuperscript{1,2,13–15} genetic diversity, and viral load kinetics at different
anatomical sites\textsuperscript{9,16,17} may cause a false-negative RT-PCR result. As a case in point, recently Baïcry et al. investigated the first negative RT-PCR results of patients showing typical COVID-19 pneumonia at CT by different severity of illness and different viral load.\textsuperscript{15}

In this study, we aimed to evaluate if the clinical manifestation at presentation, the laboratory and imaging results, and the prognosis of COVID-19 are different in patients diagnosed as COVID-19, who tested negative at the first RT-PCR, in comparison with those who tested positive. Furthermore, we evaluated if comorbid conditions patient-related or the period of arrival can influence the risk of negative testing at the first swab.

Methods

Turin province was the second most affected area in Italy during the “first wave” of the pandemic. All patients admitted at the emergency department (ED) of San Luigi Gonzaga University Hospital (Orbassano, Turin) with a suspected case of COVID-19 from March 1 to May 15, 2020, were retrospectively evaluated. Patients had consented to data collection for public health and research purposes at arrival, and the Institutional Ethics Committee approved the study (n° 5796, 15/04/2020).

Patients who tested positive for SARS-CoV-2 RT-PCR in nasal swabs were included. Patients who tested negative for SARS-CoV-2 RT-PCR at first nasal swab were included if admitted to an isolation room in COVID-19 wards or discharged at home in isolation with a clinical diagnosis of COVID-19 and fulfilled at least one epidemiological criterion or clinical criteria (Supplementary Table 1).

Test-negative COVID-19 patients were admitted to a special COVID ward area with isolation rooms to avoid the in-hospital spread of infection, and RT-PCR was repeated at 24 and 72 h after the first swab or a lower airways specimen was obtained. The presence of antibodies at a serological test after discharge was also recorded. After chart review by three experienced researchers, we excluded patients who were diagnosed otherwise at the end of the hospital stay.

For all the patients, we collected demographic data and co-morbid conditions, symptoms at presentation, time from symptom onset, results of laboratory testing, and results of imaging.

We categorized radiologic findings according to literature classification\textsuperscript{18–20} detailed in Supplementary Table 1. The presence of an irregular pleural line at lung ultrasound or CT scan was also considered.

Outcomes

We collected data about respiratory support (continue positive airway pressure [CPAP], non-invasive mechanical ventilation, and invasive mechanical ventilation), admission or transfer to a higher level of care ward (intensive care unit [ICU] or high dependency unit [HDU]), length of stay in the higher intensity of care wards, in-hospital mortality, and total length of hospital stay.

Statistical analyses

Data were described as medians and interquartile ranges for quantitative variables and as absolute frequencies and percentages for categorical variables. Based on the non-normal distribution of the data assessed by the Shapiro–Wilk test, univariate comparisons were performed using the Wilcoxon rank-sum test in the group of positives to RT-PCR versus negative to RT-PCR. For categorical variables, we performed using the Chi-squared test or Fisher’s exact test when the assumptions for conducting a chi-squared test were not met. Similarly, differences in outcomes (in-hospital mortality, ICU or HDU admission, need for respiratory support, and length of stay) were evaluated in the two groups. Moreover, multivariable logistic regression was performed to investigate confounding factors in the observed associations. Odds ratios (ORs) and 95% confidence interval (95% CI) of disease severity, comorbid conditions, and period of arrival on the result of the first RT-PCR were estimated, adjusted by age and sex. Finally, we run a sensitivity analysis in patients with moderate, severe, and critical COVID-19 (according to National Institutes of Health (NIH) classification\textsuperscript{21}) to reduce possible biases because of the inclusion of asymptomatic patients and patients without pneumonia only in the test-positive group. All tests were two sided, and a P-value <0.05 was considered significant. Analyses were performed using R version 3.4.2.\textsuperscript{22}

Results

Among patients who accessed the ED from March 1 to May 15, 2020, and consented to the study, 351 were tested with RT-PCR on a nasal swab. Two hundred and thirty-six patients (67%) tested positive, and 115 patients (32%) tested negative. All 115 met the inclusion criteria having either an epidemiological criterion or a clinical criterion and being admitted in COVID-19 ward (in isolation room) or discharged in isolation at home. Among the test-negative group, 49 of 115 patients were excluded after chart review by three experts because of a possible differential diagnosis that was found during the hospital stay, whereas 66 patients were confirmed to have COVID-19 at the end of the hospital stay (both by further testing and by clinical judgment). Among 66 patients who tested negative at the first RT-PCR, 16 patients (24%) tested positive at a further RT-PCR after a median of 11 (7–15) days, 21 (32%) patients tested persistently negative but showed the presence of antibodies, one did not repeat RT-PCR but showed the presence of antibodies, and 28 (42%) repeatedly tested negative at RT-PCR and were ruled in based on clinical diagnosis. None showed co-infection or the presence of alternative respiratory pathogens.

Two hundred and twenty-five patients overall (163 test-positive and 62 test-negative patients) were admitted to COVID-19 wards; 73 test-positive and four test-negative patients were discharged in isolation at home.

In this cohort, 86 patients overall reported to potentially have had a high-risk exposure to COVID-19 (16 were nursing home residents, 10 had close contact with a COVID-19 case, 41 were health workers, 10 had a recent hospitalization or recurrently acceded outpatient’s services [i.e. dialysis, oncology, day hospital, etc]). The presence of these epidemiological criteria was reported more frequently by test-negative patients than by test-positive patients. Clinical features of COVID-19 were present in most patients but were significantly higher in test-negative patients (65 [99%] and 212 [89%], respectively; P = 0.023). Symptom’s prevalence was similar in both groups except for gastrointestinal symptoms more reported by test-positive patients (39 [16%] vs 4 [6%]; P = 0.03). Comparison of demographic data, epidemiological criteria, clinical data, and comorbid conditions in patients grouped by the first RT-PCR result is detailed in Table 1. Cardiac diseases, neurological chronic conditions, lung cancer, diabetes, and immunosuppression were more represented in the test-negative group than in the test-positive one. Patients who tested positive at a subsequent swab (n = 16) showed no significant differences in comorbid conditions compared with those who tested persistently negative (n = 50).

Laboratory tests at arrival showed that test-positive patients had a lower level of white blood cells (6.02 [4.59–8.13] vs 7.62 [5.12–11.50] × 10\textsuperscript{9}/µL; P = 0.02) and higher lymphocyte count (1324.50 [1009.50–1789.50] vs 1120.00 [820.00–1710.00]/µL; P = 0.013), whereas lactate dehydrogenase levels were not
significantly different in the two groups. The degree of respiratory failure assessed by oxygen partial pressure (PO2), partial pressure of carbon dioxide (PCO2), and the ratio PO2/fraction of inspired oxygen (PO2/FiO2) at arrival was also similar.

Overall, 178 (75%) test-positive and 56 (84%) test-negative patients underwent lung ultrasound (LUS) at arrival; 210 (88%) test-positive and 61 (92%) test-negative patients had a chest X-Ray (CXR); CT was performed in 50 (21%) test-positive and 20 (30%) test-negative patients.

In Table 2, compared results of laboratory tests, imaging, and COVID-19 severity according to NIH classification21 in test-positive and test-negative patients are reported. An LUS pattern of bilateral interstitial syndrome was prevalent in test-negative patients, followed by consolidation, whereas consolidation and unilateral

| Table 1 | Comparison of demographic data, epidemiological criteria, clinical data, and comorbid conditions in patients grouped by the first RT-PCR result. |
|---------|-------------------------------------------------------------------------------------|
| Variable | Positive RT-PCR | Negative RT-PCR | P        |
| N       | 236 | 66 | | 0.161* |
| Age, median [IQR] | 65.65 [52.57–79.10] | 72.76 [55.41–81.32] | | |
| Sex, n (%) | | | | 0.069* |
| Male | 124 (52.5) | 43 (65.2) | | |
| Female | 112 (47.5) | 23 (34.8) | | |
| Epidemiological criteria, n (%) | | | 0.093* |
| No | 175 (74.2) | 42 (63.6) | | |
| Yes | 61 (25.8) | 24 (36.4) | | |
| Epidemiological criteria specification, n (%) | | | <0.001** |
| Contact to COVID | 2 (3.3) | 8 (33.3) | | |
| Nursing home resident | 8 (13.1) | 8 (33.3) | | |
| Repeated health care services users (dialysis, day hospital) | 14 (23.0) | 4 (16.7) | | |
| Health worker | 37 (60.7) | 4 (16.7) | | |
| Clinical criteria, n (%) | | | 0.023* |
| No | 24 (11.0) | 1 (1.0) | | |
| Yes | 212 (89.0) | 65 (99.0) | | |
| Cough, dyspnea, n (%) | | | 0.515* |
| No | 62 (26.3) | 20 (30.3) | | |
| Yes | 174 (73.7) | 46 (69.7) | | |
| Fever, n (%) | | | 0.177* |
| No | 59 (25.0) | 22 (33.3) | | |
| Yes | 177 (75.0) | 44 (66.7) | | |
| Hyposmia, hypogeusia, n (%) | | | 0.491* |
| No | 227 (96.2) | 62 (93.9) | | |
| Yes | 9 (3.8) | 4 (6.1) | | |
| Nausea, vomiting, diarrhea, n (%) | | | 0.030* |
| No | 197 (83.5) | 62 (93.9) | | |
| Yes | 39 (16.5) | 4 (6.1) | | |
| Time from the onset of symptoms, median [IQR] | 4.00 [2.00–7.00] | 3.50 [2.00–8.00] | | 0.943* |
| Comorbidities | | | |
| Hypertension, n (%) | | | 0.243* |
| No | 130 (5.1) | 31 (47.0) | | |
| Yes | 106 (44.9) | 35 (53.0) | | |
| Cardiopathy, n (%) | | | 0.01* |
| No | 197 (83.5) | 43 (65.2) | | |
| Yes | 39 (16.5) | 23 (34.8) | | |
| Chronic obstructive pulmonary disease, n (%) | | | 0.357* |
| No | 202 (85.6) | 60 (90.9) | | |
| Yes | 34 (14.4) | 6 (9.1) | | |
| Lung fibrosis, n (%) | | | 0.390* |
| No | 235 (99.6) | 65 (98.5) | | |
| Yes | 1 (0.4) | 1 (1.5) | | |
| Lung cancer, n (%) | | | 0.043* |
| No | 233 (98.7) | 62 (93.9) | | |
| Yes | 3 (1.3) | 4 (6.1) | | |
| Cancer, n (%) | | | 0.121* |
| No | 210 (89.0) | 54 (81.8) | | |
| Yes | 26 (11.0) | 12 (18.2) | | |
| Immunosuppression, n (%) | | | <0.001* |
| No | 227 (96.2) | 52 (78.8) | | |
| Yes | 9 (3.8) | 14 (21.2) | | |
| Neurological disorders, n (%) | | | 0.014* |
| No | 202 (85.6) | 48 (72.7) | | |
| Yes | 34 (14.4) | 18 (27.3) | | |
| Diabetes or other metabolic conditions, n (%) | | | 0.001* |
| No | 194 (82.2) | 42 (63.6) | | |
| Yes | 42 (17.8) | 24 (36.4) | | |
| Renal failure, n (%) | | | 0.711* |
| No | 220 (93.2) | 60 (90.9) | | |
| Yes | 16 (6.8) | 6 (9.1) | | |

Data are described as absolute frequencies and percentages (in brackets) for categorical variables and as median and interquartile range [IQR] for quantitative variables. Comparisons are made with: #: Wilcoxon rank-sum test; /: Chi-squared test; x: Fisher’s exact test.
interstitial syndrome prevailed in test-negative patients followed by bilateral interstitial syndrome. Interestingly, 27% of test-positive patients had a normal LUS pattern. Non-specific findings prevailed in test-positive patients at CXR, whereas interstitial syndrome was prevalent in test-negative patients. Eighty percent of patients only, those who turned positive afterward or who showed a typical pattern at CT.15

A logistic regression was performed, including sex, age, co-morbid conditions, severity, and the period of arrival (see Fig. 1). Patients admitted to the ED at the end of April had 3.58 (1.10—12.76; $P = 0.040$) times the risk of testing negative at the first RT-PCR, those arriving in May had 7.66 (1.48—36.17; $P = 0.007$) times the risk of testing negative at the first RT-PCR, compared with those admitted at the beginning of march. Moreover, the risk of testing negative increases of 1.65 (1.24—2.24; $P = 0.001$) times with the increase of comorbid conditions.

**Discussion**

In this study, we aimed to characterize a subgroup of COVID-19 patients, who tested negative at the first RT-PCR and represent nearly 20% of our sample, in accordance with previous studies.27,29,30 Observational studies, instead, usually have considered as false-negative patients only, those who tested positive afterward or who showed a typical pattern at CT.15

---

**Table 2**

Comparison of laboratory test, imaging results, and severity in patients grouped by the first RT-PCR result.

| Variable                                      | Positive RT-PCR | Negative RT-PCR | $P$   |
|-----------------------------------------------|-----------------|-----------------|-------|
| **Laboratory test**, median [IQR]             |                 |                 |       |
| PO2 at arrival (mm Hg)                        | 77.00 [60.00—94.75] | 71.00 [61.00—82.00] | 0.093*|
| PCO2 at arrival (mm Hg)                       | 34.50 [31.00—38.00] | 35.00 [32.00—38.30] | 0.334*|
| P/F at arrival                                | 314.29 [235.71—392.86] | 319.05 [250.00—369.05] | 0.748*|
| Total WBC (K/μL)                              | 6.02 [4.59—8.13] | 7.62 [5.12—11.50] | 0.0026*|
| Lymphocytes (μL)                              | 1124.50 [1009.50—1789.50] | 1120.00 [820.00—1710.00] | 0.013*|
| LDH (U/L)                                     | 330.50 [218.50—449.25] | 288.50 [243.75—380.75] | 0.5266*|
| **Imaging results**, n (%)                    |                 |                 |       |
| Chest X-ray (n = 271)                         |                 |                 |       |
| Pneumonia consolidation                       | 40 (19.0)       | 15 (24.6)       | <0.001*|
| Interstitial syndrome                         | 18 (8.6)        | 19 (31.1)       |       |
| Aspecific findings                            | 87 (41.4)       | 15 (24.6)       |       |
| Normal CXR                                    | 65 (31.0)       | 12 (19.7)       |       |
| Lung ultrasound (n = 234)                     |                 |                 |       |
| Consolidation                                 | 54 (30.3)       | 13 (23.2)       | <0.001*|
| Monolateral interstitial syndrome             | 41 (23.0)       | 6 (10.7)        |       |
| Bilateral interstitial syndrome               | 34 (19.1)       | 26 (46.4)       |       |
| Pleural effusion                              | 0 (0.0)         | 7 (12.5)        |       |
| Normal lung ultrasound                        | 49 (27.5)       | 4 (7.1)         |       |
| CT scan (n = 70)                              |                 |                 |       |
| Typical pattern                               | 16 (80.0)       | 29 (58.0)       | 0.012*|
| Atypical pattern                              | 0 (0.0)         | 5 (10.0)        |       |
| Undetermined                                  | 2 (10.0)        | 16 (32.0)       |       |
| Normal CT scan                                | 2 (10.0)        | 0 (0.0)         |       |
| Irregular pleural line (n = 243)              |                 |                 |       |
| No                                           | 157 (84.0)      | 48 (85.7)       | 0.751*|
| Yes                                          | 30 (16.0)       | 8 (14.3)        |       |
| COVID-19 severity (NIH classification)        |                 |                 | 0.001*|
| Asymptomatic                                  | 16 (7)          | 0 (0)           |       |
| Mild illness                                  | 43 (18)         | 3 (5)           |       |
| Moderate illness                              | 90 (36)         | 35 (53)         |       |
| Severe illness                                | 70 (30)         | 26 (39)         |       |
| Critical illness                              | 17 (7)          | 2 (3)           |       |

Abbreviations: PO2 = oxygen partial pressure; PCO2 = partial pressure of carbon dioxide; P/F ratio = PO2/fraction of inspired oxygen (FiO2); wbc = white blood cells, LDH = lactate dehydrogenases, CT = computed tomography. Data are described as absolute frequencies and percentages (in brackets) for categorical variables and as median and interquartile range [IQR] for quantitative variables. Comparisons are made with: #: Wilcoxon rank-sum test; :: Chi-squared test; ;; Fisher’s exact test.
Data are described as absolute frequencies and percentages (in brackets) for categorical variables and as median and interquartile range \[IQR\] for quantitative variables.

In our cohort, patients negative at the first RT-PCR had similar demographic characteristics and similar symptoms if compared with RT-PCR positive cases, except for gastroenteric symptoms. Test-positive patients showed more leukopenia and lymphocytosis, in agreement with Brendish et al.;\(^{14}\) on the contrary, symptoms, the severity of respiratory impairment, and laboratory findings were similar in the test-positive and the test-negative group. A possible explanation may be found in the different designs and populations of the two studies: Brendish et al. included patients with respiratory symptoms with a differential diagnosis (a higher prevalence of smokers and chronic obstructive pulmonary disease), and they did not intend to compare false negative to RT-PCR cases with the confirmed COVID-19 cases.\(^{14}\)

In our cohort, test-negative patients showed a higher prevalence of very typical patterns at LUS and CXR when compared with test-positive patients: this evidence remains when restricting the analysis to patients presenting with pneumonia (moderate, severe, or critical illness according to NIH classification\(^{21}\)). We agree with other authors on the use of imaging to achieve a proper detection of cases\(^{3,5,9}\) and acknowledge that having signs of interstitial pneumonia at LUS was prevalent in test-negative patients and could guide case definition. Similarly, we found that epidemiological factors in the history of false-negative patients were more represented.

When evaluating outcomes, corrected by severity, test-positive and test-negative patients showed a similar need for respiratory support and mortality rate. Nevertheless, the test-positive group showed a higher rate of admission in ICU/HDU, whereas most test-negative patients were admitted to general wards. We might hypothesize that test-positive patients had a higher viral load, which was seen to be related to more severe disease and a higher rate of detection by RT-PCR,\(^{14,17}\) but this explanation needs further validation.

Regarding possible individual characteristics that could influence a false-negative result at RT-PCR, immunosuppression, as well as other comorbid conditions, such as cardiopathy and metabolic conditions, were associated with false-negative results at RT-PCR.

To our knowledge, this is the first study to attempt to evaluate the effect of comorbid conditions on the possibility of having a negative swab. Other authors previously described merely case series\(^{24,26}\) or evaluated possible effects of comorbid conditions on viral clearances.\(^{27,29}\) The logistic regression confirmed that patients with more comorbid conditions had an increased risk of testing negative at the first RT-PCR.

The timing of the assay from symptom onset is known to influence the rate of RT-PCR positivity,\(^{13,16,30}\) but in our cohort was similar among test-negative and test-positive patients. As Lippi et al.,\(^{13}\) we assumed that technical issues in swab collection, transport, and analysis could have reduced the efficiency of swab tests in the first phase of the pandemic because of the overload of laboratories. On the contrary, we observed an increase in false negative in the late phase of the pandemic, which may be explained by a better clinical understanding of this illness.

Moreover, in the latter phase of pandemics in Piedmont, we admitted mainly older patients, often affected by multiple comorbid conditions,\(^{28}\) who are at higher risk of testing negative. This trend is consistent with our findings that false-negative RT-PCR COVID-19 patients present more comorbidities compared with the positive cohort and, in line with a previous meta-analysis, that older age may affect RT-PCR sensitivity.\(^{18,29}\)

As other authors,\(^{2,24}\) we described RT-PCR-negative cases both during the first weeks of the first wave, when patients showed typical phenotypes, and later when we observed many atypical cases in older patients with a great burden of comorbid conditions.\(^{24,25,28}\) The concurrence of atypical imaging patterns and clinical courses with negative microbiological results was challenging for the emergency physician in the later phase of the first Italian pandemic wave. We suggest that in patients with associated comorbid conditions, a comprehensive evaluation of laboratory results (leukopenia) and imaging (LUS and CT) may help to define cases that could be misdiagnosed by RT-PCR alone.

In our cohort, patients negative at the first RT-PCR had similar demographic characteristics and similar symptoms if compared with RT-PCR positive cases, except for gastroenteric symptoms. Test-positive patients showed more leukopenia and lymphocytosis, in agreement with Brendish et al.;\(^{14}\) on the contrary, symptoms, the severity of respiratory impairment, and laboratory findings were similar in the test-positive and the test-negative group. A possible explanation may be found in the different designs and populations of the two studies: Brendish et al. included patients with respiratory symptoms with a differential diagnosis (a higher prevalence of smokers and chronic obstructive pulmonary disease), and they did not intend to compare false negative to RT-PCR cases with the confirmed COVID-19 cases.\(^{14}\)

In our cohort, test-negative patients showed a higher prevalence of very typical patterns at LUS and CXR when compared with test-positive patients: this evidence remains when restricting the analysis to patients presenting with pneumonia (moderate, severe, or critical illness according to NIH classification\(^{21}\)). We agree with other authors on the use of imaging to achieve a proper detection of cases\(^{3,5,9}\) and acknowledge that having signs of interstitial pneumonia at LUS was prevalent in test-negative patients and could guide case definition. Similarly, we found that epidemiological factors in the history of false-negative patients were more represented.

When evaluating outcomes, corrected by severity, test-positive and test-negative patients showed a similar need for respiratory support and mortality rate. Nevertheless, the test-positive group showed a higher rate of admission in ICU/HDU, whereas most test-negative patients were admitted to general wards. We might hypothesize that test-positive patients had a higher viral load, which was seen to be related to more severe disease and a higher rate of detection by RT-PCR,\(^{14,17}\) but this explanation needs further validation.

Regarding possible individual characteristics that could influence a false-negative result at RT-PCR, immunosuppression, as well as other comorbid conditions, such as cardiopathy and metabolic conditions, were associated with false-negative results at RT-PCR.

To our knowledge, this is the first study to attempt to evaluate the effect of comorbid conditions on the possibility of having a negative swab. Other authors previously described merely case series\(^{24,26}\) or evaluated possible effects of comorbid conditions on viral clearances.\(^{27,29}\) The logistic regression confirmed that patients with more comorbid conditions had an increased risk of testing negative at the first RT-PCR.

The timing of the assay from symptom onset is known to influence the rate of RT-PCR positivity,\(^{13,16,30}\) but in our cohort was similar among test-negative and test-positive patients. As Lippi et al.,\(^{13}\) we assumed that technical issues in swab collection, transport, and analysis could have reduced the efficiency of swab tests in the first phase of the pandemic because of the overload of laboratories. On the contrary, we observed an increase in false negative in the late phase of the pandemic, which may be explained by a better clinical understanding of this illness.

Moreover, in the latter phase of pandemics in Piedmont, we admitted mainly older patients, often affected by multiple comorbid conditions,\(^{28}\) who are at higher risk of testing negative. This trend is consistent with our findings that false-negative RT-PCR COVID-19 patients present more comorbidities compared with the positive cohort and, in line with a previous meta-analysis, that older age may affect RT-PCR sensitivity.\(^{18,29}\)

As other authors,\(^{2,24}\) we described RT-PCR-negative cases both during the first weeks of the first wave, when patients showed typical phenotypes, and later when we observed many atypical cases in older patients with a great burden of comorbid conditions.\(^{24,25,28}\) The concurrence of atypical imaging patterns and clinical courses with negative microbiological results was challenging for the emergency physician in the later phase of the first Italian pandemic wave. We suggest that in patients with associated comorbid conditions, a comprehensive evaluation of laboratory results (leukopenia) and imaging (LUS and CT) may help to define cases that could be misdiagnosed by RT-PCR alone.
Our findings must be interpreted bearing in mind that the data were collected at the very beginning of the pandemic crisis: in a similar context of uncertainties, both clinical experience and diagnostic performance of laboratory tests were rapidly evolving. In the following months, organizational and technological improvements have reduced many preanalytical and analytical issues reducing the rate of false-negative RT-PCR test. Thanks to the shared observations on false-negative cases, our colleagues were more confident in using lung ultrasound and in interpreting clinical, laboratory, and imaging findings, and in case of any discordant result, we implemented the diagnostic algorithm using antigenic testing, the evaluation of IgM antibodies, and the interpretation of cycle threshold value for RT-PCR to achieve diagnostic confirmation.

It would be of interest to confirm with further studies if the improvement in highly sensitive and specific tests or a combination of the newly available assays has reduced the incidence of “false-negative” at first RT-PCR during the subsequent pandemic waves.

Strengths and limitations

To the best of our knowledge, this is the first study to compare symptoms, comorbid conditions, and clinical variables in a broad cohort of COVID-19 cases with both positive and negative RT-PCR at the arrival in the ED. Moreover, it was previously unknown which possible modifier increases the risk of testing negative at RT-PCR. To avoid the comparison of two groups of patients at different stages of their clinical history of COVID-19 disease, we performed a sensitivity analysis restricted to moderate, severe, and critical COVID-19 cases confirming the results of the whole population.

This study has limitations: first, the single-center experience and the limited proportion of RT-PCR negatives compared with the other group. Then, its retrospective nature and the fact that serologic assays for SARS-CoV-2 were approved in Italy at the end of April limited the possibility of having our patients tested for SARS-CoV-2 antibodies. We tried to overcome the lack of laboratory confirmation of cases with a careful clinical evaluation by three experienced physicians to warrant an accurate group definition.

**Author statements**

**Ethical approval**

The Institutional Ethics Committee approved the study (n° 5796, 15/04/2020).

**Funding**

None declared.

**Competing interests**

None declared.

**Availability of data and material**

Available on request.

**Appendix A. Supplementary data**

Supplementary data to this article can be found online at https://doi.org/10.1016/j.puhe.2021.09.010.

**References**

1. Carpenter CR, Mudd PA, West CP, Wilber E, Wilber ST. Diagnosing COVID-19 in the emergency department: a scoping review of clinical examinations, laboratory tests, imaging accuracy, and biases. *Acad Emerg Med* 2020 Jun 16; https://doi.org/10.1111/acem.14048. 10.1111/acem.14048. Epub ahead of print. PMID: 32542934; PMCID: PMC7323136.

2. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Euro Surveill* 2020 Jan; 25(3):2000045. https://doi.org/10.2807/1560-7917.ES.2020.25.3.2000045.

3. Kucirka LM, Lauer SA, Laeyendecker O, Boon D, Lessler J. Variation in false-negative rate of Reverse Transcriptase Polymerase Chain reaction-based SARS-CoV-2 tests by time since exposure. *Ann Intern Med* 2020 Aug 18; 173(4):262–7. https://doi.org/10.7326/M20-1495. Epub 2020 May 13. PMID: 32422057; PMCID: PMC7240870.

4. Tang YM, Schmitz JE, Persing DH, Stratton CW. Laboratory diagnosis of COVID-19: Current issues and challenges. *J Clin Microbiol* 2020 May 26; 58(6): e00512–20. https://doi.org/10.1128/JCM.00512-20. PMID: 32245835; PMCID: PMC769383.

5. Xie X, Zhong Z, Zhao W, Zheng C, Wang F, Liu J. Chest CT for typical coronavirus disease 2019 (COVID-19) pneumonia: Relationship to negative RT-PCR testing.
12. Kanji JN, Zelyas N, MacDonald C, Pabbaraju K, Khan MN, Prasad A, et al. False negative nasopharyngeal and oropharyngeal swabs do not Rule out COVID-19. J Clin Microbiol 2020 Apr 23;58(5). doi: 10.1128/JCM.00297-20. e00297-20 PMID: 32102856; PMCID: PMC7180262.

13. Lippi G, Simundic AM, Plebani M. Potential preanalytical and analytical vulnerabilities in the laboratory diagnosis of coronavirus disease 2019 (COVID-19). Mayo Clin Proc 2020 Apr 20. PMID: 32373325; PMCID: PMC7183249.

14. Brendish NJ, Poole S, Liu SS, Sales P, Gooma A, Limsukon A, et al. Negative nasopharyngeal and oropharyngeal swab tests do not rule out COVID-19 in China: a report of 1014 cases. Radiology 2020 Aug 19;296(2):E312–40. https://doi.org/10.1148/radiol.2020200642. Epub 2020 Feb 26. PMID: 32101510; PMCID: PMC7233399.

15. Lippi G, Sanchis-Gomar F, Henry BM. Repeated testing in SARS-CoV-2 infection. J Glob Health 2020 Jun;10(1):010347. doi: 10.7189/jogh.10.010347. PMID: 32373325; PMCID: PMC7183249.

16. Tahamtan A, Ardebili A. Real-time RT-PCR in COVID-19 detection: issues affecting the results. Expert Rev Mol Diagn 2020 Sep;20(9):989–1004. https://doi.org/10.1080/14737659.2020.1193313. Epub 2020 Jun 29. PMID: 32980038; PMCID: PMC7521430.

17. Mallett S, Allen AJ, Graziadio S, Taylor SA, Sakai NS, Green K, et al. At what times during infection is SARS-CoV-2 detectable and no longer detectable using RT-PCR-based tests? A systematic review of individual participant data. BMC Med 2020 Nov 4;18(1):1346. https://doi.org/10.1186/s12196-020-01810-8. PMID: 33143712; PMCID: PMC7609379.

18. Kim H, Hong H, Yoon SH. Diagnostic performance of CT and Reverse transcriptase-polymerase chain reaction for coronavirus disease 2019: a meta-analysis. Radiology 2020 Sep;296(3):E145–55. https://doi.org/10.1148/radiol.2020201343. Epub 2020 Apr 17. PMID: 32301646; PMCID: PMC7233409.

19. Simpson S, Kay FI, Abbara S, Bhalla S, Chung JH, Chung M, et al. Radiological society of north america expert consensus statement on reporting chest CT findings related to COVID-19. Endorsed by the society of thoracic radiology, the american college of radiology, and rsna - secondary publication. J Thorac Imaging 2020 Jul;35(4):219–27. https://doi.org/10.1097/RTI.0000000000000524. PMID: 32324653; PMCID: PMC7255403.

20. Lomoro P, Verde F, Zerboni F, Simonetti I, Borghi C, Fachinetti C, et al. COVID-19 pneumonia manifestations at the admission on chest ultrasound, radiographs, and CT: single-center study and comprehensive radiologic literature review. Eur J Radiol Open 2020 Jul;7:100231. https://doi.org/10.1016/j.ejoro.2020.06.002. Epub 2020 Apr 4. PMID: 32289051; PMCID: PMC7129441.

21. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at: https://www.covid19treatmentguidelines.nih.gov/. Accessed 26/02/2021.

22. R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2017. https://www.R-project.org.

23. Ingrid Arevalo-Rodriguez, Diana Buitrago-Garcia, Daniel Simancas-Racines, Paula Zambrano-Achig, Rosa del Campo, Agustín Ciapponi et al. False negative results of initial RT-PCR assays for COVID-19: a systematic review. medRxiv 2020.04.16.20066787; doi: https://doi.org/10.1101/2020.04.16.20066787.

24. Di Paolo M, Iacovelli A, Olmari F, Menichini I, Oliva A, Carnevalini M, et al. False-negative RT-PCR in SARS-CoV-2 disease: experience from an Italian COVID-19 unit. J Clin Microbiol 2020 Jul 13;58(2). doi: 10.1128/JCM.00241-20. Epub 2020 Jun 2. PMID: 32685435; PMCID: PMC7357270.

25. Poggioli E, Vercellad A, Vadalac GB, Schiavo R, Mazzoni S, Ioannilli E, et al. Negative nasopharyngeal swabs in COVID-19 pneumonia: the experience of an Italian Emergency Department (Piacenza) during the first month of the Italian epidemic. Acta Biomed 2020 Sep 7;91(3):e20200224. https://doi.org/10.23750/abm.v91i3.9979. PMID: 32912720.

26. Trisnawati Ika, El Khair Riat, Ayu Puspitarani Dyah, Rifqi Faiza Aditya, Gunadi. Prolonged nucleic acid conversion and false-negative RT-PCR results in patients with COVID-19: a case series. Ann Med Surg 2020;59:224–8. https://doi.org/10.1016/j.amsu.2020.09.040. ISSN 2049-0801.

27. Pal R, Banerjee M, Are with uncontrolled diabetes mellitus at high risk of reinfections with COVID-19? Prim Care Diabetes 2021 Feb;15(1):1–18. https://doi.org/10.1016/j.pcd.2020.08.002. Epub 2020 Aug 7. PMID: 32800450; PMCID: PMC7412302.

28. Caramello V, Macciotta A, De Salve AV, Gobbi V, Ruffino TM, Mazzetti G, et al. Clinical characteristics and management of COVID-19 patients accessing the emergency department in a hospital in Northern Italy in March and April 2020. Epidemiol Prev 2020 Sep-Dec;44(5-6 Suppl 2):208–15. https://doi.org/10.19191/EP20.5-6.S2.120. English PMID: 33412812.

29. Xiao AT, Tong YX, Zhang S. False negative of RT-PCR and prolonged nucleic acid conversion in COVID-19: rather than recurrence. J Med Virol 2020 Oct;92(10):1755–6. https://doi.org/10.1002/jmv.25835. Epub 2020 Jul 11. PMID: 32270882; PMCID: PMC7262304.

30. Wikramaratna PS, Paton RS, Ghafari M, Lourenço J. Estimating the false-negative test probability of SARS-CoV-2 by RT-PCR. Euro Surveill 2020 Dec;25(50):2000568. https://doi.org/10.2807/1560-7917.ES.2020.35.20.2000568. PMID: 33343398; PMCID: PMC7812420.